| Previous close | 32.20 |
| Open | 32.61 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 80.00 |
| Expiry date | 2023-02-17 |
| Day's range | 32.20 - 32.61 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
- GlobeNewswire
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral brepocitinib generated statistically significant and clinically meaningful resultsPriovant is developing brepocitinib in severe autoimmune diseases with few approved therapies and where dual inhibition of TYK2 and JAK1 may provide greater efficacy than inhibiting either aloneA single registrational Phase 3 trial evaluating oral brepocitinib in derm
- Yahoo Finance
States could ban abortion pill for Medicaid enrollees, experts say
States could sidestep FDA-approved abortion pills after the Supreme Court overturned Roe v. Wade. But it remains to be seen if the federal government can enforce access.
© 2022 Yahoo. All rights reserved.
